Authors
Silke Gillessen, Fabio Turco, Ian D Davis, Jason A Efstathiou, Louise Emmett, Karim Fizazi, Nicholas D James, Neal Shore, Eric J Small, Matthew Smith, Christopher J Sweeney, Bertrand F Tombal, Jochen Walz, Thomas Zilli, Hui-Ming Lin, Martino Pedrani, Marialuisa Puglisi, Vérane Achard, Neeraj Agarwal, Rahul Aggarwal, Emmanuel S Antonarakis, Ana Aparicio, Andrew J Armstrong, Diogo Assed Bastos, Gerhardt Attard, Karol Axcrona, Mouna Ayadi, Atul Batra, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Fabrice Bossaert, Maria T Bourlon, Erik Briers, Alberto Briganti, Consuelo Buttigliero, Daniel Castellano, Elena Castro, Heather H Cheng, Kim N Chi, Edmund Chiong, Noel Clarke, Phil Cornford, Bo Dai, Maria De Santis, André Deschamps, Ignacio Duran, Onyeanunam N Ekeke, Tamer I H El Nahas, Stefano Fanti, Omolara A Fatiregun, Andre Fay, Peter C Fong, Valerie Fonteyne, Nicola Fossati, Giulio Francolini, Stephen Freedland, Maria Natalia Gandur Quiroga, Daniel J George, Gianluca Giannarini, Martin E Gleave, Gwenaelle Gravis, Kirsten Greene, Boris Hadaschik, Lukman Hakim, Susan Halabi, Isabel Heidegger, Daniel Heinrich, Ken Herrmann, Michael S Hofman, Sung Kyu Hong, Thomas A Hope, Lisa G Horvath, Maha H A Hussain, Barbara A Jereczek-Fossa, Brian Jones, Robert J Jones, Anthony M Joshua, Ravindran Kanesvaran, Daniel Keizman, Raja B Khauli, Glen Kristiansen, Joshua Lang, Andrew Loblaw, Stacy Loeb, Brandon A Mahal, Fernando C Maluf, Joaquin Mateo, David Matheson, Mika P Matikainen, Ray McDermott, Rana R McKay, Niven Mehra, Axel Stuart Merseburger, Jeff Michalski, Alicia K Morgans, Michael J Morris, Hind Mrabti, Deborah Mukherji, Declan G Murphy, Vedang Murthy, Shingai B A Mutambirwa, Paul L Nguyen, Joe M O'Sullivan, William K Oh, Daniela Oprea-Lager, Piet Ost, Anwar R Padhani, Channing Judith Paller, Jacob See-Tong Pang, Athanasios Papatsoris, Chris Parker, Aušvydas Patašius, Darren M C Poon, Colin C Pritchard, Danny M Rabah, Dana Rathkopf, Charles J Ryan, Amy Rylance, Fred Saad, Juan Pablo Sade, Alfred Samuels, Shahneen Sandhu, Oliver A Sartor, Edward M Schaeffer, Nina-Sophie Schmidt-Hegemann, Tyler M Seibert, Nima Sharifi, Iwona A Skoneczna, Alexandra Sokolova, Daniel E Spratt, Sandy Srinivas, Hiroyoshi Suzuki, Mary-Ellen Taplin, Camilla Thellenberg Karlsson, Derya Tilki, Hiroji Uemura, Yüksel Ürün, Nicholas van As, Roderick van den Bergh, Neha Vapiwala, Gunhild von Amsberg, Qiang Wei, Kosj Yamoah, Dingwei Ye, Evan Y Yu, Almudena Zapatero, Aurelius Omlin
Published in
European urology. Oct 26, 2026. Epub Oct 26, 2026.
Abstract
Innovations have improved outcomes in high-risk localised, locally advanced, and biochemically recurrent prostate cancer (PC), yet high-level evidence remains limited for many management decisions. The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed an international panel on key clinical questions to complement evidence-based guidelines.
Here we present the voting results for the questions on high-risk localised, locally advanced, and biochemically recurrent PC from APCCC 2026.
Before the conference, a multidisciplinary panel of 144 international PC experts used a modified Delphi process to develop 313 multiple-choice consensus questions, of which 134 covered high-risk localised and locally advanced PC, including prostate-specific antigen (PSA) persistence and PSA recurrence, and side effects of treatment. These questions were administered to the 133 voting panel members "panellists" via a web-based survey prior to the conference.
Consensus was defined a priori as ≥75% agreement, with strong consensus defined as ≥90% agreement. Overall, consensus was reached for 44 of the 134 questions (32.8%), with seven questions reaching a strong consensus. Results and limitations The voting results show varying degrees of consensus, as discussed in this article and as detailed in the Supplementary Material. An interactive heat map for the questions can be found at https://apccc.org/APCCC2026-votings-localised-and-locally-advanced-prostate-cancer/. These findings do not include a formal literature review or meta-analysis.
The voting results can help physicians and patients navigate controversial areas of clinical management for which evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Importantly, APCCC 2026 once again identified important gaps (areas of no consensus) that merit evaluation in specifically designed trials.
PMID:
42934071
Bibliographic data and abstract were imported from PubMed on 27 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 26
- Comments 0